Chapurlat R D, Duboeuf F P, Liens D, Meunier P J
INSERM Unit 403, Edouard Herriot Hospital, Lyon, France.
J Rheumatol. 1996 Sep;23(9):1557-9.
To assess the difference in bone mineral density (BMD) between pathologic and healthy legs in reflex sympathetic dystrophy syndrome (RSDS) using a whole body BMD with dual energy X-ray absorptiometry (DEXA).
Cross sectional evaluation of BMD in 55 patients with RSDS compared BMD of the affected and the healthy limb with 121 controls. Followup was performed on 21 patients treated with intravenous pamidronate.
In the cross sectional study, BMD was reduced in the dystrophic affected extremities and this reduction correlated with the duration of evolution of the disease. In the longitudinal study, BMD remained stable in patients treated with pamidronate.
The cross sectional study confirms that DEXA is not a diagnostic tool. The longitudinal study confirms DEXA is accurate, nontraumatic, rapid, and safe for longterm quantitative assessment of unilateral bone loss caused by lower limb RSDS.
使用双能X线吸收法（DEXA）进行全身骨密度测量，评估反射性交感神经营养不良综合征（RSDS）患者病变腿部与健康腿部之间的骨密度差异。
对55例RSDS患者的骨密度进行横断面评估，将患侧和健侧肢体的骨密度与121名对照者进行比较。对21例接受静脉注射帕米膦酸盐治疗的患者进行随访。
在横断面研究中，营养不良的患侧肢体骨密度降低，且这种降低与疾病进展的持续时间相关。在纵向研究中，接受帕米膦酸盐治疗的患者骨密度保持稳定。
横断面研究证实DEXA不是一种诊断工具。纵向研究证实DEXA对于下肢RSDS引起的单侧骨丢失的长期定量评估是准确、无创、快速且安全的。
